Assembly Biosciences (ASMB) said Wednesday a phase 1b trial of its drug candidate ABI-4334 showed 'strong' antiviral activity in chronic hepatitis B patients.
Two groups of 10 patients with different doses met the safety profile supporting once-daily oral dosing for a 28-day treatment, the company said, adding there were no serious adverse events or adverse events that led to the study drug discontinuation.
Assembly Biosciences also said Gilead Sciences (GILD), under its collaboration with Assembly, may opt for an exclusive license for further development based on the trial's findings.
Shares of the company were up over 1.2% in recent Wednesday premarket activity. Gilead's shares were down 0.1%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。